Johnson & Johnson released better than expected quarterly results before the markets opened on Tuesday, but it also announced a pause in its late-stage coronavirus vaccine trial.
Global confirmed cases of COVID-19 have reached 37.8 million, while the number of fatal cases is approaching 1.1 million.
Two federal agencies have awarded AstraZeneca some $486 million to develop further the company's treatment and potential vaccine for COVID-19. The payment includes delivery of 100,000 doses of the medicine.
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
According to the Microsoft Bing COVID-19 Tracker, global confirmed cases of COVID-19 have reached more than 37.5 million.
24/7 Wall St. has been reviewing many sectors for leadership heading into earnings. One area that can offer some defensive strategies is biotech and pharmaceuticals.
Medical device company Spinal Elements Holdings intends to price more than 7 million shares for an initial public offering valued up to almost $133 million.
Applied Therapeutics shares pushed higher on Thursday after a new analyst report came out supposing massive upside for this biotech.
America has posted more than 7.5 million confirmed cases of COVID-19 so far, the highest figure in the world. The number of cases in Vermont is a little over 1,800. Why is that?
Taiwan Liposome shares shot up on Wednesday after the firm announced that it would be able to move forward with its COVID-19 trial that uses hydroxychloroquine.
Eli Lilly shares made a handy gain on Wednesday after the company announced an update to its SARS-CoV-2 neutralizing antibody programs.
Announcements that Alexion Pharmaceuticals made at its virtual Investor Day about expanding its pipeline and its guidance led to a handy gain in its shares on Tuesday.
Vir Biotechnology shares jumped on Tuesday after the firm announced that it would be expanding its late-stage COVID-19 study in conjunction with GlaxoSmithKline.
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United States. While those…
ImmunoGen shares pushed higher to start out the week when the FDA provided an update for the firm’s treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
